<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119847</url>
  </required_header>
  <id_info>
    <org_study_id>221</org_study_id>
    <secondary_id>R01HL072906</secondary_id>
    <nct_id>NCT00119847</nct_id>
  </id_info>
  <brief_title>Electrophysiological Effects of Late PCI After MI</brief_title>
  <official_title>Electrophysiological Effects of Late PCI (OAT-EP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if opening blocked arteries with heart balloons and
      stents prevents heart rhythm problems in individuals 3 to 28 days after a heart attack.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      There is now unequivocal evidence that early coronary reperfusion using either thrombolytics
      or primary angioplasty results in a long-term mortality reduction among individuals who have
      had a heart attack. The benefit of early reperfusion (less than 6 hours after the heart
      attack) was initially attributed to myocardial salvage and the resultant preservation of left
      ventricular function. However, it is now known that the survival benefit associated with
      thrombolytic therapy is not consistently associated with a major improvement in left
      ventricular ejection fraction (LVEF). These observations led to the formulation of the &quot;late
      open artery hypothesis,&quot; which suggests that clinical outcomes can potentially be improved by
      late reperfusion after a heart attack. Observational clinical studies have suggested that
      late patency of the infarct-related artery (IRA) after thrombolysis is associated with a
      survival benefit that is independent of LVEF and therefore cannot be solely explained by
      salvage of myocardium. Definitive proof of the late open artery hypothesis is currently
      lacking, however, because previous studies that have evaluated late percutaneous transluminal
      coronary angioplasty (PTCA) of occluded IRAs after a heart attack have produced conflicting
      results.

      These findings led to the organization of the Occluded Artery Trial (OAT), an international,
      NHLBI-funded, randomized trial of 2,200 participants. OAT is testing the hypothesis that
      mechanical reperfusion of an occluded IRA with PTCA and percutaneous coronary intervention
      (PCI) 3 to 28 days after a heart attack in high-risk individuals will reduce mortality,
      recurrent heart attacks, and hospitalization for class IV congestive heart failure.
      Enhancement of electrical stability is one of the major mechanisms that has been proposed to
      explain the association of an open IRA with an improved prognosis independent of myocardial
      salvage.

      DESIGN NARRATIVE:

      This study is an ancillary study of OAT. It will characterize the effects of late PCI of
      occluded IRAs on the most important and clinically relevant noninvasive markers of
      vulnerability to malignant ventricular arrhythmias: heart rate variability, T wave
      variability, and signal-averaged electrocardiography. These analyses will be performed in 300
      participants at baseline, 30 days, and 1 year following a heart attack in order to determine
      the effects of late PCI on the autonomic nervous system, ventricular repolarization, and
      ventricular conduction abnormalities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-termed Fractal Scaling Exponent (Alpha 1)</measure>
    <time_frame>Baseline, one year</time_frame>
    <description>Nonlinear measurement of heart rate variability, change between baseline and 1 year is the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-wave Variability</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Variability in T wave morphology, change between baseline and one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filtered QRS Duration</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Signal-averaged ECG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Disease</condition>
  <condition>Arrhythmia</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>PCI+MED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Coronary Intervention (PCI) with angioplasty and stenting of the infarct-related artery and optimal medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal medical therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <arm_group_label>PCI+MED</arm_group_label>
    <other_name>Angioplasty and stenting of the infarct-related artery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical Therapy</intervention_name>
    <description>Guideline-directed drug therapies after MI</description>
    <arm_group_label>MED</arm_group_label>
    <arm_group_label>PCI+MED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has experienced a heart attack 3 to 28 days prior to study entry

          -  Persistently occluded IRA defined as either: 1) Thrombolysis in Myocardial Infarction
             (TIMI) 0, with no flow beyond the site of occlusion; or 2) TIMI 1, with penetration of
             dye beyond the site of occlusion without dye reaching the distal vessel

          -  LVEF less than 50% or proximal occlusion in a large vessel

          -  Normal sinus rhythm

          -  QRS duration less than 120 ms

          -  Able to return for follow-up assessment of arrhythmia markers one month and one year
             after study entry

        Exclusion Criteria:

          -  Has a clinical indication for revascularization (post-heart attack angina at rest;
             significant inducible ischemia; or significant left main or triple vessel disease
             requiring PTCA or CABG)

          -  Current serious illness or condition that limits 3-year survival

          -  Severe valvular disease

          -  Chronic total occlusion

          -  New York Heart Association Class III-IV congestive heart failure

          -  Prior left ventricular aneurysm in the recent heart attack location

          -  Is a poor candidate for PTCA/stent on the basis of angiographic or clinical criteria

          -  Cannot medically survive anticoagulation during PTCA/stent or antiplatelet therapy
             after stent

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J. Rashba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stony Brook University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rashba EJ. Assessment of ventricular repolarization abnormalities in congenital long QT syndrome. J Cardiovasc Electrophysiol. 2004 May;15(5):557-9.</citation>
    <PMID>15149425</PMID>
  </reference>
  <reference>
    <citation>Rashba EJ. Should T-wave alternans testing be used to risk stratify candidates for prophylactic implantable cardioverter-defibrillator therapy? Heart Rhythm. 2005 Mar;2(3):242-4.</citation>
    <PMID>15851311</PMID>
  </reference>
  <results_reference>
    <citation>Rashba EJ, Lamas GA, Couderc JP, Hollist SM, Dzavik V, Ruzyllo W, Fridrich V, Buller CE, Forman SA, Kufera JA, Carvalho AC, Hochman JS; OAT-EP Investigators. Electrophysiological effects of late percutaneous coronary intervention for infarct-related coronary artery occlusion: the Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP). Circulation. 2009 Feb 17;119(6):779-87. doi: 10.1161/CIRCULATIONAHA.108.808626. Epub 2009 Feb 2.</citation>
    <PMID>19188505</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 6, 2005</study_first_submitted>
  <study_first_submitted_qc>July 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <results_first_submitted>February 14, 2018</results_first_submitted>
  <results_first_submitted_qc>July 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2018</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Eric Rashba</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Stents, myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCI+Optimal Medical Therapy</title>
          <description>PCI with angioplasty and stenting of the infarct-related artery and optimal medical therapy
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
        </group>
        <group group_id="P2">
          <title>Optimal Medical Therapy</title>
          <description>Optimal medical therapy alone
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCI+Optimal Medical Therapy</title>
          <description>PCI with angioplasty and stenting of the infarct-related artery and optimal medical therapy
PCI
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
        </group>
        <group group_id="B2">
          <title>Optimal Medical Therapy</title>
          <description>Optimal medical therapy alone
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="10.5"/>
                    <measurement group_id="B2" value="57.6" spread="10.5"/>
                    <measurement group_id="B3" value="57.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short-termed Fractal Scaling Exponent (Alpha 1)</title>
        <description>Nonlinear measurement of heart rate variability, change between baseline and 1 year is the primary outcome.</description>
        <time_frame>Baseline, one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI+Optimal Medical Therapy</title>
            <description>PCI with angioplasty and stenting of the infarct-related artery and optimal medical therapy
PCI
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
          </group>
          <group group_id="O2">
            <title>Optimal Medical Therapy</title>
            <description>Optimal medical therapy alone
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
          </group>
        </group_list>
        <measure>
          <title>Short-termed Fractal Scaling Exponent (Alpha 1)</title>
          <description>Nonlinear measurement of heart rate variability, change between baseline and 1 year is the primary outcome.</description>
          <units>unit-less</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.34"/>
                    <measurement group_id="O2" value="-0.03" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The planned sample size of 300 subjects was chosen to provide 80% power to detect a clinically relevant difference of 0.1 in the change in α1 from baseline to 1 year between the 2 treatment groups on the basis of data from prior studies that indicated that baseline levels of α1 would be 1.0 with a common SD of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>p&lt;0.05 required for statistical significance</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-wave Variability</title>
        <description>Variability in T wave morphology, change between baseline and one year</description>
        <time_frame>Baseline and one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI+Optimal Medical Therapy</title>
            <description>PCI with angioplasty and stenting of the infarct-related artery and optimal medical therapy
PCI
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
          </group>
          <group group_id="O2">
            <title>Optimal Medical Therapy</title>
            <description>Optimal medical therapy alone
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
          </group>
        </group_list>
        <measure>
          <title>T-wave Variability</title>
          <description>Variability in T wave morphology, change between baseline and one year</description>
          <units>Microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="25.1"/>
                    <measurement group_id="O2" value="-3.4" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <p_value_desc>p&lt;0.01 required for statistical significance</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Filtered QRS Duration</title>
        <description>Signal-averaged ECG</description>
        <time_frame>Baseline and one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI+Optimal Medical Therapy</title>
            <description>PCI with angioplasty and stenting of the infarct-related artery and optimal medical therapy
PCI
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
          </group>
          <group group_id="O2">
            <title>Optimal Medical Therapy</title>
            <description>Optimal medical therapy alone
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
          </group>
        </group_list>
        <measure>
          <title>Filtered QRS Duration</title>
          <description>Signal-averaged ECG</description>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="12.4"/>
                    <measurement group_id="O2" value="3.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>p&lt;0.01 required for statistical significance</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PCI+Optimal Medical Therapy</title>
          <description>PCI with angioplasty and stenting of the infarct-related artery and optimal medical therapy
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
        </group>
        <group group_id="E2">
          <title>Optimal Medical Therapy</title>
          <description>Optimal medical therapy alone
Optimal Medical Therapy: Guideline-directed drug therapies after MI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric J. Rashba</name_or_title>
      <organization>Stony Brook University</organization>
      <phone>631-444-3575</phone>
      <email>eric.rashba@stonybrookmedicine.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

